证券代码：688176 证券简称：亚虹医药 公告编号：2025-038 公司及董事会对于杨明远先生在担任公司董事、董事会秘书、财务负责人期 间为公司发展所做出的重要贡献表示衷心的感谢。 江苏亚虹医药科技股份有限公司 关于公司董事兼高级管理人员离任的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏亚虹医药科技股份有限公司（以下简称"公司"）董事会于近日收到杨 明远先生的《辞任报告》，因个人原因，杨明远先生申请辞去公司董事、董事会 秘书、财务负责人职务，离任后不再担任公司任何职务。具体情况如下： | 姓名 | 离任职务 | 离任时间 | | | 原定任期到 | 离任 | 是否继续在上 市公司及其控 | 是否存在未 履行完毕的 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 期日 | 原因 | | | | | | | | | | | 股子公司任职 | 公开承诺 | | 杨明远 | 董事、董事 会秘书、财 | 2025 年 30 ...

Core Viewpoint - Yang Mingyuan has resigned from his positions as director, board secretary, and financial officer of Jiangsu Yahuang Pharmaceutical Technology Co., Ltd. for personal reasons, effective September 30, 2025, without affecting the board's normal operation [1] Group 1 - Yang Mingyuan's resignation does not reduce the number of board members below the legal requirement [1] - The company will promptly appoint a new board secretary and financial officer [1] - Until new appointments are made, the chairman and general manager Panke will act as the board secretary, while director and deputy general manager Zhuang Chengfeng John will act as the financial officer [1] Group 2 - Yang Mingyuan holds approximately 0.13% of the company's total share capital and will comply with relevant reduction regulations after his departure [1]

Core Viewpoint - The financial performance and trading activity of Yahuang Pharmaceutical indicate a mixed outlook, with significant revenue growth but ongoing net losses and high financing levels [1][2]. Group 1: Financial Performance - As of June 30, 2025, Yahuang Pharmaceutical reported a revenue of 130 million yuan, representing a year-on-year growth of 61.80% [2]. - The company recorded a net profit attributable to shareholders of -162 million yuan, which is an increase in losses by 11.84% compared to the previous period [2]. Group 2: Shareholder and Trading Activity - As of September 25, 2023, Yahuang Pharmaceutical's stock price decreased by 1.28%, with a trading volume of 66.05 million yuan [1]. - The company had a financing buy-in amount of 3.7364 million yuan and a financing repayment of 6.2467 million yuan on the same day, resulting in a net financing outflow of -2.5103 million yuan [1]. - The total balance of margin trading for Yahuang Pharmaceutical reached 209 million yuan, accounting for 4.45% of its market capitalization, which is above the 80th percentile level over the past year [1]. - The number of shareholders increased by 2.09% to 25,500, while the average circulating shares per person decreased by 2.05% to 14,857 shares [2]. - Among the top ten circulating shareholders, Penghua Medical Technology Stock A ranked as the fourth largest, holding 6.5441 million shares, an increase of 891,300 shares from the previous period [2].

证券代码：688176 证券简称：亚虹医药 公告编号：2025-037 江苏亚虹医药科技股份有限公司 2025年第二次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 9 月 23 日 （二） 股东大会召开的地点：上海市浦东新区高科西路 551 号万信酒店一楼会 议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 212 | | --- | --- | | 普通股股东人数 | 212 | | 2、出席会议的股东所持有的表决权数量 | 199,925,772 | | 普通股股东所持有表决权数量 | 199,925,772 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例（%） | 35.5421 | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 35.5421 | （四） ...

YUAN LAW OFFICES 北京 BEIJING · 上海 SHANGHAI · 深圳 SHENZHEN · 香港 HONG KONG · 广州 GUANGZHOU · 西安 XI'AN 北京市嘉源律师事务所 关于江苏亚虹医药科技股份有限公司 2025 年第二次临时股东大会的 法律意见书 西城区复兴门内大街 158 号远洋大厦 4 楼 中国 · 北京 Un - 致:江苏亚虹医药科技股份有限公司 北京市嘉源律师事务所 关于江苏亚虹医药科技股份有限公司 2025 年第二次临时股东大会的法律意见书 嘉源(2025)-04-703 北京市嘉源律师事务所(以下简称"本所")接受江苏亚虹医药科技股份有 限公司(以下简称"亚虹医药"或"公司")的委托,根据《中华人民共和国公 司法》(以下简称"《公司法》")《上市公司股东会规则》(以下简称"《股东 会规则》")等现行有效的法律、行政法规、部门规章、规范性文件(以下简称 "法律法规")以及《江苏亚虹医药科技股份有限公司章程》(以下简称"《公司 章程》"）的有关规定,指派本所律师对公司 2025 年第二次临时股东大会（以 下简称"本次股东大会"）进行见证,并依法出具本法律 ...

Core Viewpoint - The discussion at the "Innovative Progress in Cancer Treatment and New Trends in Drug Development Forum" highlighted the importance of addressing unmet medical needs in women's health, particularly in cervical cancer prevention and treatment [1] Company Summary - Aihong Pharmaceutical is focused on transforming the treatment of cervical precancerous lesions from invasive surgery to non-invasive, fertility-friendly methods [1] - The company's product APL-1702 has entered the second round of technical review by the CDE, indicating that it is in the final stages of preparation for market launch [1] - Aihong Pharmaceutical emphasizes its commitment to continuous innovation in women's health and aims to expedite the approval, access, and application of APL-1702 in the Chinese market [1]

中信证券股份有限公司 关于江苏亚虹医药科技股份有限公司 2025 年半年度持续督导跟踪报告 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为江苏亚 虹医药科技股份有限公司（以下简称"公司"或"上市公司"）首次公开发行股 票并在科创板上市的保荐人，根据《证券发行上市保荐业务管理办法》、《上海 证券交易所科创板股票上市规则》等相关规定，中信证券履行持续督导职责，并 出具 2025 年半年度（以下简称"本持续督导期间"）跟踪报告。 一、持续督导工作概述 1、保荐人制定了持续督导工作制度，制定了相应的工作计划，明确了现场 检查的工作要求。 2、保荐人已与公司签订保荐协议，该协议已明确了双方在持续督导期间的 权利义务，并报上海证券交易所备案。 3、本持续督导期间，保荐人通过与公司的日常沟通、现场回访等方式开展 持续督导工作，并于 2025 年 8 月 29 日、2025 年 9 月 3 日对公司进行了现场检 查。 4、本持续督导期间，保荐人根据相关法规和规范性文件的要求履行持续督 导职责，具体内容包括： （1）查阅公司章程、三会议事规则等公司治理制度、三会会议材料； （2）查阅公司财务管理、会计核算和内部审 ...

Group 1 - The core viewpoint of the news is that Yahuang Pharmaceutical has shown significant trading activity and financial performance, with a notable increase in revenue and a high level of financing balance [1][2] - On September 15, Yahuang Pharmaceutical's stock price decreased by 0.86%, with a trading volume of 1.05 billion yuan, and a net financing purchase of 640.96 million yuan [1] - As of September 15, the total financing and securities balance for Yahuang Pharmaceutical was 2.35 billion yuan, which represents 4.69% of its market capitalization, indicating a high level of financing activity [1] Group 2 - As of June 30, the number of shareholders for Yahuang Pharmaceutical increased to 25,500, reflecting a growth of 2.09%, while the average circulating shares per person decreased by 2.05% to 14,857 shares [2] - For the first half of 2025, Yahuang Pharmaceutical reported a revenue of 1.30 billion yuan, marking a year-on-year growth of 61.80%, although the net profit attributable to the parent company was -1.62 billion yuan, an increase of 11.84% compared to the previous period [2] - Among the top ten circulating shareholders, Penghua Medical Technology Stock A ranked as the fourth largest, holding 6.5441 million shares, which is an increase of 891,300 shares from the previous period [2]

江苏亚虹医药科技股份有限公司 2025 年第二次临时股东大会 会议资料 二〇二五年九月 1 | 《关于修订、制定公司部分治理制度的议案》 9 | | --- | 江苏亚虹医药科技股份有限公司 2025 年第二次临时股东大会须知 为了保证股东在本次股东大会依法行使职权，确保股东大会的正常秩序和 议事效率，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》《江苏亚虹医药科技股份有限公司章程》（以下简称"《公 司章程》"）、《江苏亚虹医药科技股份有限公司股东大会议事规则》等有关规 定，江苏亚虹医药科技股份有限公司（以下简称"公司"或"亚虹医药"）特制 定本次股东大会会议须知： 一、为确认出席大会的股东及股东代理人或其他出席者的出席资格，会议 工作人员将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 二、为保证本次大会的严肃性和正常秩序，切实维护股东的合法权益，请 出席大会的股东或股东代理人或其他出席者提前 30 分钟到达会场签到确认参会 资格。在会议主持人宣布现场出席会议的股东和股东代理人人数及所持有的表 决权数量之前，会议登记应当终止。会议登记终止后进场的股东无权参与现 ...

Core Viewpoint - Yahui Pharmaceutical (688176.SH) is currently experiencing a decline in stock price, closing at 11.51 yuan with a drop of 4.88%, indicating a state of share price below the initial public offering (IPO) price [1] Summary by Relevant Sections Company Overview - Yahui Pharmaceutical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on January 7, 2022, with an issuance of 110 million shares at an IPO price of 22.98 yuan per share [1] - The company is controlled by PAN KE, who serves as the chairman and general manager, holding American nationality [1] IPO Details - The total funds raised from the IPO amounted to 2.528 billion yuan, with a net amount of 2.381 billion yuan after deducting issuance costs [1] - The net funds raised exceeded the original plan by 311 million yuan, which was initially set at 2.070 billion yuan [1] - The total issuance costs were 147 million yuan, with CITIC Securities receiving 130 million yuan as underwriting and sponsorship fees [1] Stock Performance - The stock price fell below the IPO price on the first day of trading, with an intraday high of 20.00 yuan, marking the highest price since the listing [1]